Failure in a key clinical trial caused shares to tank.
Motley Fool co-founder David Gardner often says that if your stock-picking results dont beat the market, you should stick to index funds and ETFs. But is there more than one way to define beating the market?
Yes, the bankruptcy has hurt Under Armour's earnings this quarter, and probably this year. But long term, this will only be a small speed bump.
House Speaker Paul Ryan is the clear favorite to win his Wisconsin primary race on Tuesday, but regardless of the outcome the unexpectedly competitive contest serves as a stark reminder of voter concerns about his performance as leader of the GOP-controlled House.
Lowered full-year financial guidance is weighing on investors' minds today.
After banking another quarterly beat, the financial services technology company looks ahead to a stronger second half.
The social network looks to continue to follow along Google's path.
Sliding sales over the past two quarters have taken a toll on Gilead Sciences stock. Here's why it's a stronger buy than ever.
Could Vivint Solar be a strong player in residential solar again after a rough year?
Production, asset sales, and debt reduction remain the focal point.
The biotech remains in a holding pattern, awaiting decisions from the courts and the FDA before it can launch its generic version of three-times-weekly Copaxone.
Three babies at Prince George’s Hospital Center in Maryland tested positive for bacteria that could cause a potentially deadly infection after two babies died last week.
The world's oceans continue to fascinate -here are some of the awesome creatures found throughout the world.
The web-based postage company delivered impressive Q2 financial results.